NASDAQ:BDSI

BioDelivery Sciences International Stock Forecast, Price & News

$3.42
-0.05 (-1.44 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.37
Now: $3.42
$3.51
50-Day Range
$3.45
MA: $3.83
$4.41
52-Week Range
$3.04
Now: $3.42
$5.45
Volume1.40 million shs
Average Volume1.25 million shs
Market Capitalization$344.95 million
P/E Ratio24.43
Dividend YieldN/A
Beta0.72
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.
BioDelivery Sciences International logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050
Employees176
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$111.39 million
Cash Flow$0.14 per share
Book Value$0.78 per share

Profitability

Net Income$-15,310,000.00

Miscellaneous

Market Cap$344.95 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Earnings Preview: BioDelivery Sciences Intl
March 9, 2021 |  benzinga.com
Top Biotech Stocks for Q1 2021
December 9, 2020 |  finance.yahoo.com
Is a BioDelivery Sciences (BDSI) Good Value Investor Stock?
November 17, 2020 |  finance.yahoo.com
BioDelivery Sciences International
September 6, 2020 |  fool.com
See More Headlines

MarketRank

Overall MarketRank

2.11 out of 5 stars

Medical Sector

36th out of 2,025 stocks

Pharmaceutical Preparations Industry

16th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
$3.42
-0.05 (-1.44 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

Is BioDelivery Sciences International a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioDelivery Sciences International stock.
View analyst ratings for BioDelivery Sciences International
or view top-rated stocks.

What stocks does MarketBeat like better than BioDelivery Sciences International?

Wall Street analysts have given BioDelivery Sciences International a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioDelivery Sciences International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for BioDelivery Sciences International
.

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings results on Tuesday, March, 9th. The specialty pharmaceutical company reported $0.10 EPS for the quarter, topping the Zacks' consensus estimate of $0.06 by $0.04. The specialty pharmaceutical company earned $42.17 million during the quarter, compared to the consensus estimate of $38.75 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 25.04% and a net margin of 10.16%.
View BioDelivery Sciences International's earnings history
.

How has BioDelivery Sciences International's stock price been impacted by Coronavirus?

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BDSI shares have decreased by 13.6% and is now trading at $3.42.
View which stocks have been most impacted by COVID-19
.

What guidance has BioDelivery Sciences International issued on next quarter's earnings?

BioDelivery Sciences International updated its FY 2021 Pre-Market earnings guidance on Wednesday, March, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $170-180 million, compared to the consensus revenue estimate of $190.23 million.

What price target have analysts set for BDSI?

5 analysts have issued 12 month target prices for BioDelivery Sciences International's stock. Their forecasts range from $5.50 to $9.25. On average, they expect BioDelivery Sciences International's stock price to reach $8.15 in the next year. This suggests a possible upside of 138.3% from the stock's current price.
View analysts' price targets for BioDelivery Sciences International
or view top-rated stocks among Wall Street analysts.

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the following people:
  • Mr. Jeffrey Allen Bailey, CEO & Director (Age 58, Pay $599.96k)
  • Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 56, Pay $629.46k)
  • Ms. Mary Theresa Coelho, Exec. VP, CFO & Treasurer (Age 58, Pay $657.17k)
  • Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52, Pay $586.68k)
  • Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 60, Pay $570.06k)
  • Mr. Joseph M. Lockhart, Sr. VP of Operations
  • Mr. Kevin Ostrander, Sr. VP of Bus. Devel.
  • Dr. Bill McCarberg, Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Arthur G. Lipman PharmD, Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Jeff Katz, Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board

Who are some of BioDelivery Sciences International's key competitors?

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.com (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by a variety of retail and institutional investors. Top institutional investors include NEXT Financial Group Inc (0.16%) and HighPoint Advisor Group LLC (0.10%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Jeffrey Allen Bailey, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, Thomas B Smith and W Mark Watson.
View institutional ownership trends for BioDelivery Sciences International
.

Which institutional investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, James Vollins, Jeffrey Allen Bailey, Mark A Sirgo, Mary Theresa Coelho, and W Mark Watson.
View insider buying and selling activity for BioDelivery Sciences International
or view top insider-selling stocks.

Which institutional investors are buying BioDelivery Sciences International stock?

BDSI stock was acquired by a variety of institutional investors in the last quarter, including HighPoint Advisor Group LLC.
View insider buying and selling activity for BioDelivery Sciences International
or or view top insider-buying stocks.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $3.42.

How much money does BioDelivery Sciences International make?

BioDelivery Sciences International has a market capitalization of $344.95 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis.

How many employees does BioDelivery Sciences International have?

BioDelivery Sciences International employs 176 workers across the globe.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is www.bdsi.com.

Where are BioDelivery Sciences International's headquarters?

BioDelivery Sciences International is headquartered at 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.